GeneDx's Contributions at ASHG Annual Meeting
GeneDx, a leader in enhancing health outcomes through genomic insights, announced its scientific presentations at the 2024 American Society of Human Genetics (ASHG) annual meeting. With an impressive portfolio, GeneDx will showcase data from six platform presentations and five posters, unveiling research stemming from its extensive dataset of over 700,000 clinical exomes and genomes.
Leveraging Genomic Data for Pediatric Care
The company utilizes this vast database to inform several studies aimed at improving clinical care for pediatric patients. As the industry gears up for broader genomic sequencing adoption, GeneDx's collaborative efforts with organizations like SeqFirst and the University of Washington are pivotal. Their research emphasizes the accessibility and cost-effectiveness of exome and whole genome sequencing (WGS) in treating children.
Highlights of the Research Presented
Among the significant findings to be showcased at ASHG are:
Impact of Rapid Whole Genome Sequencing
In collaboration with SeqFirst, GeneDx explored patient cases diagnosed through rapid whole genome sequencing (rWGS). This analysis focused on understanding how decisions influenced genomic sequencing outcomes compared to conventional methods, highlighting the essential need for this advanced technology in NICUs.
Addressing Racial Disparities in Genetic Diagnosis
GeneDx, alongside the University of Washington and Geisinger, conducted one of the largest studies on genetic diagnoses across diverse ancestral backgrounds. This research scrutinizes whether diagnostic yields differ significantly based on genetic ancestry and investigates barriers limiting access to accurate genetic diagnoses.
Long Read Sequencing Data Validation
The clinical benefits of long read sequencing are becoming more apparent. Validation data presented at the meeting will highlight the efficacy of PacBio’s HiFi long read sequencing in identifying cases validated by short-read WGS. Additionally, the research reveals instances where long-read sequencing has identified pathogenic variants that short-read methods could not detect.
Genetic Variants and Autism Spectrum Disorder
In collaboration with the Autism Sequencing Consortium, GeneDx research has identified 230 new genes associated with Autism Spectrum Disorder (ASD). This work reinforces the reliability and precision of genetic diagnostics as compared to traditional methods that rely on caregiver reports or behavior observations.
Dr. Paul Kruszka, Chief Medical Officer at GeneDx, expressed enthusiasm regarding their contributions, stating, "Presenting these findings at ASHG illustrates GeneDx’s ongoing commitment to enhancing genomic research for clinical applications. Our partnerships with leading initiatives enable us to leverage an unparalleled dataset, pushing innovation and improving patient outcomes. This research not only reinforces the effectiveness of genomic testing but also emphasizes the necessity of equitable access across populations."
Collaboration with Renowned Institutions
GeneDx has teamed up with various esteemed institutions for several presentations at the meeting:
Key Presentations Schedule
- Wednesday, November 6, 9:15 am MT: The neuronal role of the proteasomal ATPase subunit gene PSMC5 in neurodevelopmental proteasomopathies presented by Janelle Stanton, PhD from the University of Limerick, Ireland.
- Thursday, November 7, 1:30 pm MT: Utilizing exclusion criteria for selecting critically ill newborns for rapid genome sequencing, presented by Tara Wenger, MD, PhD from the University of Washington.
- Friday, November 8, 10:45 am MT: Genome-wide profiling utilizing HiFi sequencing, presented by Xiao Chen, PhD from PacBio.
- Friday, November 8, 11:15 am MT: Comparison of detection sensitivity of pathogenic variants between long-read and short-read sequencing in clinical diagnostics by Joseph M. Devaney, PhD from GeneDx.
- Friday, November 8, 1:45 pm MT: Expanding the knowledge of autism-related genes through the largest exome study to date, presented by Frederick Satterstrom, PhD from the Broad Institute.
- Friday, November 8, 6:00 pm MT: Insights from expanded newborn screening using genome sequencing, presented by Wendy Chung, MD, PhD from Boston Children’s Hospital.
Poster Presentations of Note
- Thursday, November 7 at 2:30 pm MT: Investigating racial disparities in access to genetic diagnoses by Jessica X. Chong, PhD from the University of Washington.
- Friday, November 8 at 2:30 pm MT: Evaluating genetic factors and diagnostic yields in pediatric motor speech disorders by Marissa Mitchel, MS from Geisinger Autism & Developmental Medicine Institute.
- Friday, November 8 at 2:30 pm MT: Addressing dosage sensitivity predictions for multigenic copy number variants by Erin Riggs, MS from Geisinger.
- Friday, November 8 at 2:30 pm MT: Insights into developmental delay and associated variants through research by Karynne Patterson, BS/BA from the University of Washington.
About GeneDx
GeneDx, trading on Nasdaq under the ticker WGS, is dedicated to providing actionable insights that enhance diagnostics, streamline treatment approaches, and assist in drug discovery processes. Positioned at the forefront of genomics, GeneDx accelerates the integration of genomic data along with large-scale clinical insights, revolutionizing precision medicine as a standard of care. As the premier provider of exome and genome testing, GeneDx leverages the vast landscapes of rare disease datasets to facilitate transformative healthcare solutions.
Frequently Asked Questions
What are the main findings from GeneDx's research at ASHG?
GeneDx's research emphasizes the clinical utility of genomic sequencing, showcasing findings on rapid whole genome sequencing, racial disparities in genetic diagnoses, and new genetic variants associated with ASD.
How does GeneDx enhance pediatric healthcare?
By utilizing its extensive genomic database, GeneDx aims to improve clinical outcomes for pediatric patients, ensuring better diagnostic accuracy and treatment options.
What is long read sequencing, and why is it significant?
Long read sequencing is a method that allows for clearer detection of genomic variants that short-read sequencing may miss. This approach is increasingly important for accurate diagnoses.
Who are GeneDx's key collaborators in their research?
GeneDx collaborates with several prominent institutions like the University of Washington, SeqFirst, PacBio, and the Autism Sequencing Consortium to advance genomic research.
What is the aim of the presentations and posters at ASHG?
The presentations and posters aim to share groundbreaking research findings and enhance the understanding of genomic applications in clinical settings, particularly related to pediatric care.
